A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Dora Liu, Alexandra Ahmet, Leanne Ward, Preetha Krishnamoorthy, Efrem D Mandelcorn, Richard Leigh, Jacques P Brown, Albert Cohen, Harold Kim, Dora Liu, Alexandra Ahmet, Leanne Ward, Preetha Krishnamoorthy, Efrem D Mandelcorn, Richard Leigh, Jacques P Brown, Albert Cohen, Harold Kim

Abstract

Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing's syndrome, psychiatric disturbances and immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy, particularly when used at high doses for prolonged periods. This comprehensive article reviews these adverse events and provides practical recommendations for their prevention and management based on both current literature and the clinical experience of the authors.

References

    1. National Institute for Health and Clinical Excellence (NICE) Clinical Knowledge Summaries: Corticosteroids - Oral. NICE; 2012. [ ], Accessed February 20, 2013.
    1. Singh N, Rieder MJ, Tucker MJ. Mechanisms of glucocorticoid-mediated antiinflammatory and immunosuppressive action. Paed Perinatal Drug Ther. 2004;6:107–115.
    1. Newton R, Leigh R, Giembycz MA. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther. 2010;125:286–327. doi: 10.1016/j.pharmthera.2009.11.003.
    1. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13. doi: 10.1016/j.mce.2010.04.005.
    1. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol. 2002;135:511–519. doi: 10.1038/sj.bjp.0704474.
    1. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125:697–706. doi: 10.1016/j.mad.2004.06.010.
    1. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004;1:255–263. doi: 10.1513/pats.200402-015MS.
    1. Furst DE, Saag KG. Determinants of glucocorticoid dosing. 2013. (Up To Date 2012). .
    1. Deshmukh CT. Minimizing side effects of systemic corticosteroids in children. Indian J Dermatol Venereol Leprol. 2007;73:218–221. doi: 10.4103/0378-6323.33633.
    1. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–293. doi: 10.1136/ard.2005.038638.
    1. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274–282. doi: 10.1172/JCI2799.
    1. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674–1686. doi: 10.1002/art.23454.
    1. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res. 2000;15:1001–1005. doi: 10.1359/jbmr.2000.15.6.1001.
    1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–787. doi: 10.1007/s001980200108.
    1. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–899. doi: 10.1359/JBMR.040134.
    1. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183–190. doi: 10.1007/s12020-011-9580-0.
    1. Kaste SC, Karimova EJ, Neel MD. Osteonecrosis in children after therapy for malignancy. Am J Roentgeno. 2011;196:1011–1018. doi: 10.2214/AJR.10.6073.
    1. Barr RD, Sala A. Osteonecrosis in children and adolescents with cancer. Pediatr Blood Cancer. 2008;50(2 Suppl):483–485.
    1. Seamon J, Keller T, Saleh J, Cui Q. The pathogenesis of nontraumatic osteonecrosis. Arthritis. 2012;2012:601763.
    1. Zhao FC, Li ZR, Guo KJ. Clinical analysis of osteonecrosis of the femoral head induced by steroids. Orthop Surg. 2012;4:28–34. doi: 10.1111/j.1757-7861.2011.00163.x.
    1. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 17. The McGraw-Hill Companies, Inc; 2008. .
    1. Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet. 1967;2:856–859.
    1. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355:542–545. doi: 10.1016/S0140-6736(99)06290-X.
    1. Molimard M, Girodet PO, Pollet C, Fourrier-Réglat A, Daveluy A, Haramburu F, Fayon M, Tabarin A. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf. 2008;31:769–774. doi: 10.2165/00002018-200831090-00005.
    1. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009;28:749–756. doi: 10.1007/s10067-009-1135-x.
    1. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. doi: 10.1016/j.jaad.2005.01.010.
    1. Ortega E, Rodriguez C, Strand LJ, Segre E. Effects of cloprednol and other corticosteroids on hypothalamic-pituitary-adrenal axis function. J Int Med Res. 1976;4:326–337.
    1. Nichols T, Nugent CA, Tyler FH. Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab. 1965;25:343–349. doi: 10.1210/jcem-25-3-343.
    1. Shulman DI, Palmert MR, Kemp SF. Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics. 2007;119:e484–e494. doi: 10.1542/peds.2006-1612.
    1. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med. 1993;95:258–264. doi: 10.1016/0002-9343(93)90277-V.
    1. Einaudi S, Bertorello N, Masera N, Farinasso L, Barisone E, Rizzari C, Corrias A, Villa A, Riva F, Saracco P, Pastore G. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:537–541. doi: 10.1002/pbc.21339.
    1. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–426. doi: 10.1002/art.21984.
    1. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57:604–609. doi: 10.1016/j.jaad.2007.04.018.
    1. Huscher D, Thiele K, Gromnica-Ihle E, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124. doi: 10.1136/ard.2008.092163.
    1. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol. 1998;275:E806–E813.
    1. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101. doi: 10.1001/archinte.1994.00420010131015.
    1. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789–1796. doi: 10.1210/jc.2010-2729.
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(Suppl 1):S1–S212.
    1. American Diabetes Association. Standards of medical care in diabetes — 2012. Diabetes Care. 2012;35(Suppl 1):S11–S63.
    1. Black RL, Oglesby RB, von Sallman L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 1960;174:166–171. doi: 10.1001/jama.1960.63030020005014.
    1. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986;31:102–110. doi: 10.1016/0039-6257(86)90077-9.
    1. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–491. doi: 10.1001/archopht.1963.00960050484010.
    1. Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN, Eliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmol. 1997;104:1653–1660. doi: 10.1016/S0161-6420(97)30082-7.
    1. Schellenberg R, Adachi JDR, Bowie D, Brown J, Guenther L, Kader T, Trope GE. Oral corticosteroids in asthma: a review of benefits and risks. Can Respir J. 2007;14(Suppl C):1C–7C.
    1. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am. 2010;43:753–768. doi: 10.1016/j.otc.2010.04.003.
    1. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med. 1976;294:434–479.
    1. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632. doi: 10.1111/j.1365-2796.1994.tb00855.x.
    1. Saag KG, Furst DE. Major side effects of systemic glucocorticoids. 2013. (Up To Date 2012). .
    1. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740. doi: 10.7326/0003-4819-114-9-735.
    1. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med. 1983;309:21–24. doi: 10.1056/NEJM198307073090105.
    1. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case–control study. JAMA Intern Med. 2013;173:444–449. doi: 10.1001/jamainternmed.2013.2737.
    1. Derk CT, DeHoratius RJ. Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol. 2004;23:147–151. doi: 10.1007/s10067-003-0793-3.
    1. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–770. doi: 10.7326/0003-4819-141-10-200411160-00007.
    1. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, Walker BR. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004;90:859–865. doi: 10.1136/hrt.2003.020180.
    1. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166:1016–1020. doi: 10.1001/archinte.166.9.1016.
    1. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study. Arch Intern Med. 2009;169:1677–1683. doi: 10.1001/archinternmed.2009.297.
    1. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30:768–773. doi: 10.1016/S0190-9622(08)81508-3.
    1. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–248. doi: 10.1111/j.1365-4632.2009.04322.x.
    1. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 1994;21:1264–1267.
    1. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992;71:291–302.
    1. Svenson KL, Lithell H, Hällgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med. 1987;147:1917–1920. doi: 10.1001/archinte.1987.00370110045006.
    1. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53:528–535. doi: 10.1002/art.21329.
    1. Miller ML. Glucocorticoid-induced myopathy. 2013. (UpToDate 2013). [ ]
    1. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76:234–242. doi: 10.1016/0091-6749(85)90708-0.
    1. LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil. 1997;17:76–84. doi: 10.1097/00008483-199703000-00002.
    1. Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness. Curr Opin Crit Care. 2005;11:381–390. doi: 10.1097/01.ccx.0000168530.30702.3e.
    1. Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci. 2009;1179:19–40. doi: 10.1111/j.1749-6632.2009.04980.x.
    1. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81:1361–1367. doi: 10.4065/81.10.1361.
    1. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38:1631–1634. doi: 10.1212/WNL.38.10.1631.
    1. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004;92:500–505. doi: 10.1016/S1081-1206(10)61756-5.
    1. Swinburn CR, Wakefield JM, Newman SP, Jones PW. Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease. Br J Clin Pharmacol. 1988;26:709–713. doi: 10.1111/j.1365-2125.1988.tb05309.x.
    1. Turner R, Elson E. Sleep disorders. Steroids cause sleep disturbance. BMJ. 1993;306:1477–1478.
    1. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci. 2009;1179:41–55. doi: 10.1111/j.1749-6632.2009.04981.x.
    1. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47:1396–1402. doi: 10.1212/WNL.47.6.1396.
    1. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics. 1989;30:135–139. doi: 10.1016/S0033-3182(89)72293-3.
    1. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61:104–107. doi: 10.1212/WNL.61.1.104.
    1. Goggans FC, Weisberg LJ, Koran LM. Lithium prophylaxis of prednisone psychosis: a case report. J Clin Psychiatry. 1983;44:111–112.
    1. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963. doi: 10.1093/clinids/11.6.954.
    1. Saag KG. Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2012;70(Suppl 1):21–25.
    1. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–2339. doi: 10.1001/jama.2011.1692.
    1. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994;93:967–976. doi: 10.1016/S0091-6749(94)70043-5.
    1. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25:699–717. doi: 10.1016/S0889-8529(05)70348-0.
    1. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol. 1994;8:667–670. doi: 10.1007/BF00869084.
    1. Falcini F, Taccetti G, Trapani S, Tafi L, Volpi M. Growth retardation in juvenile chronic arthritis patients treated with steroids. Clin Exp Rheumatol. 1991;9:37–40.
    1. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373–380. doi: 10.1097/00005176-199305000-00005.
    1. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000;342:851–859. doi: 10.1056/NEJM200003233421204.
    1. Miller W, Achermann J, Frankland AW. In: Pediatric Endocrinology. 3. Sperling M, editor. Philadelphia: Saunders; 2008. The adrenal cortex and its disorders; pp. 444–511.
    1. Canadian Pediatric Society. Canadian Paediatric Surveillance Program (CPSP): 2010 results. CPS; PHAC; 2010. [ ], Accessed March 5, 2013.
    1. Canadian Pediatric Society. Canadian Paediatric Surveillance Program (CPSP): 2011 results. CPS; PHAC; 2011. [ ], Accessed March 5, 2013.
    1. Canadian Pediatric Society. Canadian Paediatric Surveillance Program (CPSP): 2012 results. CPS; PHAC; 2012. [ ], Accessed May 14, 2013.
    1. Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol. 2011;7:13. doi: 10.1186/1710-1492-7-13.
    1. Rix M, Birkebaek NH, Rosthoj S, Clausen N. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test. J Pediatr. 2005;147:645–650. doi: 10.1016/j.jpeds.2005.06.006.
    1. Gordijn MS, Gemke RJ, van Dalen EC, Rotteveel J, Kaspers GJ. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2012;5 CD008727.
    1. Wood JB, Frankland AW, James VH, Landon J. A rapid test of adrenocortical function. Lancet. 1965;1:243–245.
    1. Plager JE, Cushman P Jr. Suppression of the pituitary-ACTH response in man by administration of ACTH or cortisol. J Clin Endocrinol Metab. 1962;22:147–154. doi: 10.1210/jcem-22-2-147.
    1. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976;55:39–65. doi: 10.1097/00005792-197601000-00003.
    1. Amed S, Dean H, Sellers EA, Panagiotopoulos C, Shah BR, Booth GL, Laubscher TA, Dannenbaum D, Hadjiyannakis S, Hamilton JK. Risk factors for medication-induced diabetes and type 2 diabetes. J Pediatr. 2011;159:291–296. doi: 10.1016/j.jpeds.2011.01.017.
    1. Ho J, Pacaud D. Secondary diabetes in children. Can J Diab. 2004;28:400–405.
    1. Stratakis CA. Cushing syndrome in pediatrics. Endocrinol Metab Clin North Am. 2012;41:793–803. doi: 10.1016/j.ecl.2012.08.002.
    1. Semeao EJ, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk factors for low bone mineral density in children and young adults with Crohn’s disease. J Pediatr. 1999;135:593–600. doi: 10.1016/S0022-3476(99)70058-2.
    1. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 1998;42:188–194. doi: 10.1136/gut.42.2.188.
    1. Kotaniemi A, Savolainen A, Kautiainen H, Kröger H. Estimation of central osteopenia in children with chronic polyarthritis treated with glucocorticoids. Pediatrics. 1993;91:1127–1130.
    1. Bhudhikanok GS, Wang M-C, Marcus R, Harkins A, Moss RB, Bachrach LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr. 1998;133:18–27. doi: 10.1016/S0022-3476(98)70172-6.
    1. Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith AH, Haigh I. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax. 2000;55:798–804. doi: 10.1136/thorax.55.9.798.
    1. Bardare M, Bianchi ML, Furia M, Gandolini GG, Cohen E, Montesano A. Bone mineral metabolism in juvenile chronic arthritis: the influence of steroids. Clin Exp Rheumatol. 1991;9(Suppl 6):29–31.
    1. Fantini F, Beltrametti P, Gallazzi M, Gattinara M, Gerloni V, Murelli M, Parrini M. Evaluation by dual-photon absorptiometry of bone mineral loss in rheumatic children on long-term treatment with corticosteroids. Clin Exp Rheumatol. 1991;9(Suppl 6):21–28.
    1. Perez MD, Abrams SA, Loddeke L, Shypailo R, Ellis KJ. Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy X-ray absorptiometry. J Rheumatol. 2000;27(Suppl 58):38–43.
    1. van Staa TP, Cooper C, Leufken HGM, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18:913–918. doi: 10.1359/jbmr.2003.18.5.913.
    1. Halton J, Gaboury I, Grant R, Alos N, Cummings EA, Matzinger M, Shenouda N, Lentle B, Abish S, Atkinson S, Cairney E, Dix D, Israels S, Stephure D, Wilson B, Hay J, Moher D, Rauch F, Siminoski K, Ward LM. Canadian STOPP Consortium. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res. 2009;24:1326–1334. doi: 10.1359/jbmr.090202.
    1. Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM. Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010;62:516–526. doi: 10.1002/acr.20171.
    1. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R, Miettunen PM, Roth J, Atkinson SA, Couch R, Cummings EA, Dent PB, Ellsworth J, Hay J, Houghton K, Jurencak R, Larché M, LeBlanc C, Oen K, Saint-Cyr C, Stein R, Stephure D, Taback S, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM. Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study. Arthritis Care Res (Hoboken) 2012;64:122–131. doi: 10.1002/acr.20589.
    1. Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM. Canadian STOPP Consortium. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporos Int. 2012;23:751–760. doi: 10.1007/s00198-011-1621-2.
    1. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD. Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182:1864–1873. doi: 10.1503/cmaj.100771.
    1. Rodrigues Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, Gonçalves H, Danowski JS, Marques Neto JF, Mendonça LM, Bezerra MC, Terreri MT, Imamura M, Weingrill P, Plapler PG, Radominski S, Tourinho T, Szejnfeld VL, Andrada NC. Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52:580–593. doi: 10.1590/S0482-50042012000400009.
    1. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–1526. doi: 10.1002/acr.20295.
    1. National Osteoporosis Guideline Group. Osteoporosis: Clinical guideline for prevention and treatment. Updated July, 2010. National Osteoporosis Guideline Group; 2010. [ ], Accessed March 8, 2013.
    1. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. [ ], Accessed March 8, 2013.
    1. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809–816. doi: 10.1007/s00198-010-1524-7.
    1. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child. 2002;87:93–96. doi: 10.1136/adc.87.2.93.
    1. Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab. 1993;76:1188–1191. doi: 10.1210/jc.76.5.1188.
    1. Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998;83:2350–2354. doi: 10.1210/jc.83.7.2350.
    1. Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab. 1995;80:1301–1305. doi: 10.1210/jc.80.4.1301.
    1. Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N. Low-dose (1 microgram) adrenocorticotropin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000;52:633–640. doi: 10.1046/j.1365-2265.2000.00984.x.
    1. Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule SG, Tordjman K. Consortium for Evaluation of Corticotropin Test in Hypothalamic-Pituitary Adrenal Insufficiency. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a meta-analysis. J Clin Endocrinol Metab. 2008;93:4245–4253. doi: 10.1210/jc.2008-0710.
    1. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–167. doi: 10.1016/j.cjca.2012.11.032.
    1. Davidson J, Wilkinson AH, Dantal J, Dotta F, Haller H, Hernández D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC. International Expert Panel. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;7:SS3–SS24.
    1. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. doi: 10.1111/j.1398-9995.2004.00772.x.
    1. Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, Fitzgerald M, Leigh R, Watson W, Boulet LP. Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can Respir J. 2012;19:127–164.
    1. Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2006;17:8–19. doi: 10.1007/s00198-005-2032-z.
    1. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y. Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004) J Bone Miner Metab. 2005;23:105–109. doi: 10.1007/s00774-004-0596-x.
    1. National Osteoporosis Society & Royal College of Physicians Guidelines Working Group for Bone and Tooth Society. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians; 2002.
    1. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000;2:CD001347.
    1. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382–387. doi: 10.1056/NEJM199708073370603.
    1. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292–299. doi: 10.1056/NEJM199807303390502.
    1. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–2318. doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>;2-K.
    1. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277–285. doi: 10.1007/s002230001146.
    1. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253–1263. doi: 10.1016/S0140-6736(09)60250-6.
    1. Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:1083–1090. doi: 10.1007/s00198-011-1800-1.
    1. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med. 2007;357:2028–2039. doi: 10.1056/NEJMoa071408.
    1. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six–month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–3355. doi: 10.1002/art.24879.
    1. Karras D, Stoykov I, Lems WF, Langdahl BL, Ljunggren Ö, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Marin F. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol. 2012;39:600–609. doi: 10.3899/jrheum.110947.
    1. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;2:CD001983.
    1. European Medicines Agency. Calcitonin [bulletin] 2013. July 2012 [ ]
    1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–645. doi: 10.1001/jama.282.7.637.
    1. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009;60:1427–1437. doi: 10.1002/art.24445.
    1. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R. Denosumab RA Study Group. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69:872–875. doi: 10.1136/ard.2009.112920.
    1. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765. doi: 10.1056/NEJMoa0809493.
    1. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Román Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701. doi: 10.1002/jbmr.1479.
    1. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;2:CD000952.
    1. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930. doi: 10.1210/jc.2011-0385.
    1. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;4:CD005324.
    1. Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94:400–409. doi: 10.1210/jc.2008-1531.
    1. Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int. 2012;23:2703–2711. doi: 10.1007/s00198-012-1911-3.
    1. Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn’s disease. Pediatr Int. 2010;52:754–761. doi: 10.1111/j.1442-200X.2010.03174.x.
    1. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with non-traumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87:2155–2159. doi: 10.2106/JBJS.D.02959.
    1. Agarwala S, Shah SB. Ten year followup of avascular necrosis of femoral head treated with alendronate for 3 years. J Arthroplasty. 2011;26:1128–1134. doi: 10.1016/j.arth.2010.11.010.
    1. Chen CH, Chang JK, Lai KA, Hou SM, Chang CH, Wang GJ. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:1572–1578. doi: 10.1002/art.33498.
    1. Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL) Pediatr Blood Cancer. 2010;54:934–940.
    1. Leblicq C, Laverdière C, Décarie JC, Delisle JF, Isler MH, Moghrabi A, Chabot G, Alos N. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:741–747. doi: 10.1002/pbc.24313.
    1. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287:236–240. doi: 10.1001/jama.287.2.236.
    1. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg. 1994;219:416–425. doi: 10.1097/00000658-199404000-00013.
    1. Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf) 2002;57:185–191. doi: 10.1046/j.1365-2265.2002.01580.x.
    1. Allen DB, Julius JR, Breen TJ. Treatment of glucocorticoid-induced growth suppression with growth hormone. On behalf of the National Cooperative Growth Study. J Clin Endocrinol Metab. 1998;83:2824–2829. doi: 10.1210/jc.83.8.2824.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다